

Statement from Professor Stephen Livesey, Chief Scientific Officer, Australian Stem Cell Centre (ASCC)

In relation to media reports on 22 June 2006 on use of “contaminated AlloDerm”

- The ASCC received a small quantity of AlloDerm, solely for research purposes, which was from the batch under investigation by the FDA. None of this material was used by the ASCC. All of the material in question was returned to the United States immediately after notification of a voluntary recall by LifeCell in October 2005.
- LifeCell has advised the ASCC that none of the material under investigation by the FDA has been used clinically or for research in Australia.
- The sole extent of the ASCC’s use of AlloDerm has been confined to simple storage with the intent of using it for research purposes only. It is intended that this AlloDerm will be eventually used in the ASCC’s tissue repair program which aims to develop methods for delivery of stem cells for treatment of human diseases and tissue damage. Particular applications of the technologies being developed by the ASCC aim to treat spinal cord injury and neurotrauma.
- More than 700,000 patients worldwide have been successfully treated with AlloDerm since 1993. AlloDerm is a tissue repair product that has been available to patients who have suffered a serious injury or from a disfiguring disease.

22 June 2006